SlideShare a Scribd company logo
1 of 1
DETERMINATION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE (LCAT) AND
CHOLESTEROL-ESTER TRANSFER PROTEIN (CETP) ACTIVITY IN PATIENTS WITH COLORECTAL
CANCER
Marija Petrović, Jovana Jovanović, Tamara Gojković, Sandra Vladimirov, Vesna Spasojević-Kalimanovska, Aleksandra
Zeljković, Jelena Vekić, Zorana Jelić-Ivanović
Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade
Background: Lecithin-cholesterol acyltransferase (LCAT) is a
plasma enzyme that performs the esterification of free
cholesterol to cholesterol esters while cholesterol ester transfer
protein (CETP) enables the exchange of cholesterol esters and
triglycerides between HDL and triglyceride-rich lipoproteins in
rerverse transport of cholesterol.
Aim: The objective of this work was to examine the activity of
LCAT and CETP in human plasma in patients with colorectal
cancer and compare it with the control group.
Material and methods:The study included 30 healthy
people (KG) and 79 patients that have been diagnosed
with colorectal cancer (CRC). LCAT activity is obtained by
mathematical calculation of the difference between free
(FC) and esterified cholesterol (EC) concentration before
and after a 2-hour incubation of the samples at 37°C,
while the CETP-mediated transfer of cholesterol esters
was measured as the difference between the rate of
decrease in FC in the whole plasma and the rate of EC
increase in HDL during 2 hours of incubation at 37 °C.
Concentrations of FC and EC were determined by
colorimetric method with automatic analyzer ILAB 300+.Results:
Table 1. Biochemical parameters and LCAT and CETP activity in CG and CRC patients
˚ Data are presented as
mean ± standard deviation
˚˚ Data are presented as the
geometric mean (95%
confidence interval)
˚˚˚ Data are shown as
median (interquartile range)
Conclusion: The results of this study showed that there were significant differences in the activities of LCAT and CETP
between the KG and patients with CRC, which could indicate the activity disturbance of these enzyme and the consequent
disruption in the process of reverse cholesterol transport in patients with CRC.
KG CRC p
Age˚(years) 58,8±5,7 65,6±10,4 p<0,01
BMI˚(kg/m2) 27,2±5,3 25,4±3,8 p<0,05
TC˚(mmol/l) 6,09±1,14 4,58±1,37 p<0,05
HDL˚(mmol/l) 1,25±0,30 1,21±0,41 p=0,65
LDL˚(mmol/l) 2,40±0,60 2,24±0,81 p=0,33
TG˚˚(mmol/l) 1,41 (0,08-0,22) 1,20 (0,03-0,12) p=0,09
CETP˚˚˚ (µmol/l/h) -10,17 (-33,17-54,58) 39,29 (-14,19-74,31) p<0,05
LCAT˚˚˚(µmol/l/h) 100,5 (70,62-125,76) 67,0 (44,33-92,67) p>0,05
Figure 1 - CETP activity in CG and CRC
patients
Figure 2 – LCAT activity in CG and CRC
patients
LCAT
correlations
Total
cholesterol
LDL
ρ 0,276 0,236
p 0,021 0,05
Table 2 – Correlation between
LCAT and CETP activity and
lipid parameters
p≤ 0,05
p> 0,05
CETP
correlations
HDL
ρ -0,446
p <0,05

More Related Content

Similar to LCAT CETP POSTER hyatt

Biochemistry tom murray (poster)
Biochemistry tom murray (poster)Biochemistry tom murray (poster)
Biochemistry tom murray (poster)
Tommurray111
 
Automated SPE for Capillary Microsampling Poster
Automated SPE for Capillary Microsampling PosterAutomated SPE for Capillary Microsampling Poster
Automated SPE for Capillary Microsampling Poster
Rick Youngblood
 
Abstract_SMODIA2015_Acharjee_et_al
Abstract_SMODIA2015_Acharjee_et_alAbstract_SMODIA2015_Acharjee_et_al
Abstract_SMODIA2015_Acharjee_et_al
Benjamin Jenkins
 
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
SSR Institute of International Journal of Life Sciences
 
Actual Final Poster_AndyLalka
Actual Final Poster_AndyLalkaActual Final Poster_AndyLalka
Actual Final Poster_AndyLalka
Andy Lalka
 
Cystatin C as a marker of Cardio metabolic disorder in obese South Indian ind...
Cystatin C as a marker of Cardio metabolic disorder in obese South Indian ind...Cystatin C as a marker of Cardio metabolic disorder in obese South Indian ind...
Cystatin C as a marker of Cardio metabolic disorder in obese South Indian ind...
iosrjce
 
INLIGHT App Note 37
INLIGHT App Note 37INLIGHT App Note 37
INLIGHT App Note 37
Amber Cook
 

Similar to LCAT CETP POSTER hyatt (20)

Biochemistry tom murray (poster)
Biochemistry tom murray (poster)Biochemistry tom murray (poster)
Biochemistry tom murray (poster)
 
Metformin presentation sigma xi
Metformin presentation sigma xiMetformin presentation sigma xi
Metformin presentation sigma xi
 
Quantification of a Novel Peptide, CPT31 in Rat and Monkey Plasma by LC-MS
Quantification of a Novel Peptide, CPT31 in Rat and Monkey Plasma by LC-MSQuantification of a Novel Peptide, CPT31 in Rat and Monkey Plasma by LC-MS
Quantification of a Novel Peptide, CPT31 in Rat and Monkey Plasma by LC-MS
 
Impaired mitochondrial beta-oxidation in patients with chronic hepatitis C: r...
Impaired mitochondrial beta-oxidation in patients with chronic hepatitis C: r...Impaired mitochondrial beta-oxidation in patients with chronic hepatitis C: r...
Impaired mitochondrial beta-oxidation in patients with chronic hepatitis C: r...
 
Modelling and monitoring of intervention
Modelling and monitoring of interventionModelling and monitoring of intervention
Modelling and monitoring of intervention
 
Meld scoring
Meld scoringMeld scoring
Meld scoring
 
Sr Creatinine estimation journal dr.prathy.pptx
Sr Creatinine estimation journal dr.prathy.pptxSr Creatinine estimation journal dr.prathy.pptx
Sr Creatinine estimation journal dr.prathy.pptx
 
Rodent Models of Pharmacotherapy and Chronotherapy for Obesity and Cardiometa...
Rodent Models of Pharmacotherapy and Chronotherapy for Obesity and Cardiometa...Rodent Models of Pharmacotherapy and Chronotherapy for Obesity and Cardiometa...
Rodent Models of Pharmacotherapy and Chronotherapy for Obesity and Cardiometa...
 
CETP inhibitors Future in lipid management
CETP inhibitors Future in lipid managementCETP inhibitors Future in lipid management
CETP inhibitors Future in lipid management
 
Automated SPE for Capillary Microsampling Poster
Automated SPE for Capillary Microsampling PosterAutomated SPE for Capillary Microsampling Poster
Automated SPE for Capillary Microsampling Poster
 
Modelling metabolic fluxes
Modelling metabolic fluxesModelling metabolic fluxes
Modelling metabolic fluxes
 
Plasma exchange
Plasma exchangePlasma exchange
Plasma exchange
 
Abstract_SMODIA2015_Acharjee_et_al
Abstract_SMODIA2015_Acharjee_et_alAbstract_SMODIA2015_Acharjee_et_al
Abstract_SMODIA2015_Acharjee_et_al
 
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
 
Lymphoma: Treatment Updates
Lymphoma: Treatment UpdatesLymphoma: Treatment Updates
Lymphoma: Treatment Updates
 
Actual Final Poster_AndyLalka
Actual Final Poster_AndyLalkaActual Final Poster_AndyLalka
Actual Final Poster_AndyLalka
 
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
Symposium presentation:  Development of a Dried Blood Spot Method for LeptinSymposium presentation:  Development of a Dried Blood Spot Method for Leptin
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
 
Cystatin C as a marker of Cardio metabolic disorder in obese South Indian ind...
Cystatin C as a marker of Cardio metabolic disorder in obese South Indian ind...Cystatin C as a marker of Cardio metabolic disorder in obese South Indian ind...
Cystatin C as a marker of Cardio metabolic disorder in obese South Indian ind...
 
B04609014
B04609014B04609014
B04609014
 
INLIGHT App Note 37
INLIGHT App Note 37INLIGHT App Note 37
INLIGHT App Note 37
 

LCAT CETP POSTER hyatt

  • 1. DETERMINATION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE (LCAT) AND CHOLESTEROL-ESTER TRANSFER PROTEIN (CETP) ACTIVITY IN PATIENTS WITH COLORECTAL CANCER Marija Petrović, Jovana Jovanović, Tamara Gojković, Sandra Vladimirov, Vesna Spasojević-Kalimanovska, Aleksandra Zeljković, Jelena Vekić, Zorana Jelić-Ivanović Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade Background: Lecithin-cholesterol acyltransferase (LCAT) is a plasma enzyme that performs the esterification of free cholesterol to cholesterol esters while cholesterol ester transfer protein (CETP) enables the exchange of cholesterol esters and triglycerides between HDL and triglyceride-rich lipoproteins in rerverse transport of cholesterol. Aim: The objective of this work was to examine the activity of LCAT and CETP in human plasma in patients with colorectal cancer and compare it with the control group. Material and methods:The study included 30 healthy people (KG) and 79 patients that have been diagnosed with colorectal cancer (CRC). LCAT activity is obtained by mathematical calculation of the difference between free (FC) and esterified cholesterol (EC) concentration before and after a 2-hour incubation of the samples at 37°C, while the CETP-mediated transfer of cholesterol esters was measured as the difference between the rate of decrease in FC in the whole plasma and the rate of EC increase in HDL during 2 hours of incubation at 37 °C. Concentrations of FC and EC were determined by colorimetric method with automatic analyzer ILAB 300+.Results: Table 1. Biochemical parameters and LCAT and CETP activity in CG and CRC patients ˚ Data are presented as mean ± standard deviation ˚˚ Data are presented as the geometric mean (95% confidence interval) ˚˚˚ Data are shown as median (interquartile range) Conclusion: The results of this study showed that there were significant differences in the activities of LCAT and CETP between the KG and patients with CRC, which could indicate the activity disturbance of these enzyme and the consequent disruption in the process of reverse cholesterol transport in patients with CRC. KG CRC p Age˚(years) 58,8±5,7 65,6±10,4 p<0,01 BMI˚(kg/m2) 27,2±5,3 25,4±3,8 p<0,05 TC˚(mmol/l) 6,09±1,14 4,58±1,37 p<0,05 HDL˚(mmol/l) 1,25±0,30 1,21±0,41 p=0,65 LDL˚(mmol/l) 2,40±0,60 2,24±0,81 p=0,33 TG˚˚(mmol/l) 1,41 (0,08-0,22) 1,20 (0,03-0,12) p=0,09 CETP˚˚˚ (µmol/l/h) -10,17 (-33,17-54,58) 39,29 (-14,19-74,31) p<0,05 LCAT˚˚˚(µmol/l/h) 100,5 (70,62-125,76) 67,0 (44,33-92,67) p>0,05 Figure 1 - CETP activity in CG and CRC patients Figure 2 – LCAT activity in CG and CRC patients LCAT correlations Total cholesterol LDL ρ 0,276 0,236 p 0,021 0,05 Table 2 – Correlation between LCAT and CETP activity and lipid parameters p≤ 0,05 p> 0,05 CETP correlations HDL ρ -0,446 p <0,05